94 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author박찬혁-
dc.date.accessioned2019-11-27T20:44:20Z-
dc.date.available2019-11-27T20:44:20Z-
dc.date.issued2017-07-
dc.identifier.citationALIMENTARY PHARMACOLOGY & THERAPEUTICS, v. 46, no. 2, page. 106-114en_US
dc.identifier.issn0269-2813-
dc.identifier.issn1365-2036-
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/full/10.1111/apt.14130-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/115004-
dc.description.abstractBackground: In order to increase eradication rates, vonoprazan, a novel potassium-competitive acid blocker, has been used in Helicobacter pylori eradication therapy. Aim: To summarise the results of the efficacy of vonoprazan-based triple therapy, helping clinicians to better understand the benefit of vonoprazan in the treatment of H. pylori infection. Methods: We conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords "vonoprazan," "takecab", "TAK438," "potassium," "competitive," "potassium-competitive," "Helicobacter," and "pylori." Studies were included if they evaluated the eradication rate between the vonoprazan-based and proton pump inhibitor (PPI)-based triple therapies. Results: Ten studies and 10 644 patients were evaluated. The crude H. pylori eradication rate determined by intention-to-treat analysis was 87.9% and 72.8% in the vonoprazan-based triple therapy and PPI-based triple therapy respectively. The eradication rate of the vonoprazan-based triple therapy was superior to that of the PPI-based triple therapy (pooled risk ratio [RR] [95% confidence interval (CI)]=1.19 [1.15-1.24]) In addition, there was no significant difference in dropout rate due to adverse event between the regimens (pooled RR of the vonoprazan-based triple therapy [95% CI]= 0.69 [0.23-2.03]). The incidence of any adverse events also did not differ between the regimens (pooled RR [95% CI]= 1.02 [0.78-1.34]). Conclusions: The vonoprazan-based triple therapy showed superior efficacy in terms of H. pylori eradication as compared to the PPI-based triple therapy. In addition, the vonoprazan-based triple therapy showed comparable tolerability and incidence of adverse events.en_US
dc.description.sponsorshipThis work was supported by the research fund of Hanyang University (HY-2016)en_US
dc.language.isoen_USen_US
dc.publisherWILEYen_US
dc.subjectCOMPETITIVE ACID BLOCKERen_US
dc.subjectPROTON PUMP INHIBITORSen_US
dc.subjectRANDOMIZED CLINICAL-TRIALen_US
dc.subjectVS. LANSOPRAZOLEen_US
dc.subjectGUIDELINESen_US
dc.subjectRESISTANCEen_US
dc.subject1ST-LINEen_US
dc.subjectKOREAen_US
dc.subjectESOMEPRAZOLEen_US
dc.titleSystematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradicationen_US
dc.typeArticleen_US
dc.relation.no2-
dc.relation.volume46-
dc.identifier.doi10.1111/apt.14130-
dc.relation.page106-114-
dc.relation.journalALIMENTARY PHARMACOLOGY & THERAPEUTICS-
dc.contributor.googleauthorJung, Y. S.-
dc.contributor.googleauthorKim, E. H.-
dc.contributor.googleauthorPark, C. H.-
dc.relation.code2017002174-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidchan100-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE